SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation

Summary

This study is a multicenter, single arm phase I / II clinical study in mCRPC subjects who failed to receive docetaxel chemotherapy, abitolone acetate and / or enzalutamide (including its analogues) for the treatment of BRCA mutations in germ cells and / or somatic cells.

Timeline

Start

2020-08-30

Primary completion

2021-12-30

Completion

2022-06-30

Drugs

Indications